Form 4 for NGNE Neurogene Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-20 · accession 0001543663-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-24 | 2026-02-20 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +22.0K | 114.6K | +24% | $0 |
| D | 2026-02-24 | 2026-02-20 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +131.9K | 131.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-20 | A | A | 22,000 | $0.00 | 114,643 | D | — | — | (F1) Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. (F2) Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-20 | A | A | 131,900 | $0.00 | 131,900 | D | $17.64 · — to 2036-02-20 | 131,900 Common Stock | (F3) This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. |